|Bid||32.81 x 1500|
|Ask||33.48 x 1300|
|Day's Range||32.95 - 33.45|
|52 Week Range||29.83 - 35.38|
|PE Ratio (TTM)||27.74|
|Dividend & Yield||1.28 (3.84%)|
|1y Target Est||N/A|
TRENTON, N.J. (AP) — The Food and Drug Administration has approved a new medicine for use against a rare, rapidly progressing blood cancer after other treatments have failed.
The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's rare blood cancer drug, Besponsa, with a boxed warning. Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.